NIH Directors Pioneer Award (DP1 Clinical Trial Optional)

The NIH Director's Pioneer Award is a federal funding opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services. It is part of the NIH Common Fund and specifically falls under the High-Risk, High-Reward Research program. This initiative is designed to support individual scientists who demonstrate exceptional creativity and propose pioneering research ideas that have the potential to produce major impacts across broad areas of biomedical and health-related science. The program emphasizes transformative thinking and innovation rather than incremental advances, encouraging applicants to pursue bold and unconventional approaches. The primary objective of the Pioneer Award is to enable researchers to explore novel scientific directions that differ substantially from their current work or from established approaches in the field. Projects may span basic, translational, or clinical research, provided they align with the NIH mission to enhance human health. Importantly, applicants are not required to submit preliminary data or detailed experimental plans. Instead, the application focuses on the investigator’s vision, creativity, and potential for high-impact contributions. The award is intended to catalyze new lines of inquiry rather than extend existing research programs. Funding for the Pioneer Award consists of $700000 in direct costs per year for a project period of five years, totaling $3500000 in direct funding, with additional indirect costs provided separately. Approximately seven awards are expected to be made, contingent upon funding availability and the quality of applications received. Funds may be used for personnel, equipment, supplies, data management, and other allowable research expenses. There is no cost sharing or matching requirement associated with this opportunity. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of domestic organizations such as higher education institutions, nonprofits, for-profit entities, and various levels of government agencies. Individual applicants must serve as the sole Program Director or Principal Investigator, and only one application per individual is permitted. Foreign organizations are not eligible to apply, although certain non-funded international collaborations may be allowed under specific conditions. Applicants must also meet registration requirements including SAM, eRA Commons, Grants.gov, and ORCID. The application process requires submission through approved electronic systems such as Grants.gov or NIH ASSIST. Applicants must adhere strictly to NIH application guidelines and provide a structured essay describing their innovative vision, qualifications, and how their proposed work represents a significant departure from existing research. Three confidential letters of reference are also required and must be submitted separately by designated referees. Additional required components include a Data Management and Sharing Plan and compliance with all registration and submission protocols. Applications are evaluated through a rigorous peer review process that prioritizes the significance and innovation of the proposed research, the investigator’s track record of creativity, and the potential for transformative impact. Selected applicants may be invited for interviews as part of the review process. Final funding decisions consider scientific merit, program priorities, and available funding. The timeline for this opportunity includes an application opening date in early August 2026, a submission deadline in early September 2026, and anticipated project start dates in mid-2027. This funding opportunity does not recur on a fixed schedule but is periodically reissued by NIH.

Focus on highly innovative transformative research ideas and demonstrate a clear departure from prior work while emphasizing investigator creativity and impact potential